1-10 of 10
Martin H. Kropff
Close
Sort by
Journal Articles

Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma

Stefan Knop, MD, Peter Liebisch, MD, Holger Hebart, MD, Ernst Holler, MD, Monika Engelhardt, MD, Bernd Metzner, MD, Dietrich Peest, MD, Walter Aulitzky, MD, Donald W. Bunjes, MD, Christian Straka, MD, Thomas Fischer, MD, Hannes Wandt, MD, Orhan Sezer, MD, Markus Hentrich, MD, Helmut Ostermann, MD, Christian Peschel, MD, Georg Hess, MD, Bernd Hertenstein, MD, Mathias Freund, MD, Martin H Kropff, MD, Hans-Heinrich Wolf, MD, Wolfram E Jung, MD, Norbert Frickhofen, MD, Ralf C. Bargou, Georg Maschmeyer, MD, Else Heidemann, MD, Christian Langer, MD, Lothar Kanz, MD, Christoph Meisner, PhD, Hermann Einsele, MD
Journal: Blood
Blood (2014) 124 (21): 43.
https://doi.org/10.1182/blood.V124.21.43.43
Published: 2014
Journal Articles

Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial.

Stefan Knop, MD, Peter Liebisch, MD, Holger Hebart, Ernst Holler, PhD, Monika Engelhardt, Ralf C Bargou, MD, Bernd Metzner, Dietrich Peest, Walter E. Aulitzky, MD, Hannes Wandt, MD, Orhan Sezer, MD, PhD, Markus Hentrich, Helmut Ostermann, Christian Peschel, MD, Georg Hess, Bernd Hertenstein, Mathias Freund, MD, Martin H Kropff, Hans-Heinrich Wolf, Wolfram Jung, Norbert Frickhofen, MD, Georg Maschmeyer, Hans-Guenther Mergenthaler, Else Heidemann, Nicolaus Kröger, MD, Christian Straka, Corinna Engel, Lothar Kanz, Christoph Meisner, Hermann Einsele, MD
Journal: Blood
Blood (2009) 114 (22): 51.
https://doi.org/10.1182/blood.V114.22.51.51
Published: 2009
Journal Articles

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Jesus F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie-Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Paul Richardson
Journal: Blood
Blood (2008) 112 (11): 650.
https://doi.org/10.1182/blood.V112.11.650.650
Published: 2008
Journal Articles

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul Richardson, Rudolf Schlag, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Rik Schots, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F San Miguel
Journal: Blood
Blood (2008) 112 (11): 2778.
https://doi.org/10.1182/blood.V112.11.2778.2778
Published: 2008
Journal Articles

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Meletios A Dimopoulos, Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin H Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A Alexeeva, Rik Schots, Tamas Masszi, Maria-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesus F San Miguel
Journal: Blood
Blood (2008) 112 (11): 1727.
https://doi.org/10.1182/blood.V112.11.1727.1727
Published: 2008
Journal Articles

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Maria Teresa Petrucci, Victor A Rossiev, Jian Hou, Tadeusz Robak, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F. San Miguel
Journal: Blood
Blood (2008) 112 (11): 1741.
https://doi.org/10.1182/blood.V112.11.1741.1741
Published: 2008
Journal Articles

Imexon (AOP 99.0001) for Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study

Thomas M. Moehler, Anatoli Golenkov, MD, Heinz Ludwig, Martin H Kropff, Nuriet K Khuageva, E. A Osmanov, I. Broen, MD, H. Goldschmidt
Journal: Blood
Blood (2008) 112 (11): 5195.
https://doi.org/10.1182/blood.V112.11.5195.5195
Published: 2008
Journal Articles

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Guido Bisping, MD, Doris Wenning, Martin H. Kropff, MD, Gerd Munzert, MD, Frank Hilberg, PhD, Gerald J. Roth, PhD, Wolfgang E. Berdel, MD, Joachim Kienast, MD
Journal: Blood
Blood (2005) 106 (11): 112.
https://doi.org/10.1182/blood.V106.11.112.112
Published: 2005
Journal Articles

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Martin H. Kropff, MD, Guido Bisping, MD, Doris Wenning, Wolfgang E. Berdel, MD, Joachim Kienast, MD
Journal: Blood
Blood (2004) 104 (11): 4923.
https://doi.org/10.1182/blood.V104.11.4923.4923
Published: 2004
Journal Articles

Myeloma: targeted therapies march on

Martin H. Kropff, Joachim Kienast
Journal: Blood
Blood (2004) 103 (9): 3247–3248.
https://doi.org/10.1182/blood-2004-02-0658
Published: 2004